Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1
Trial details
- Registry ID
- NCT07486934
- Phase
- Phase 3
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1NCT07486934 | Dyne Therapeutics | Phase 3 | Recruiting | 2028-07Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |